ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
ALX Oncology (Nasdaq: ALXO) announced that results from their Phase 1b/2 trial combining evorpacept with zanidatamab in HER2-positive and HER2-low metastatic breast cancer will be presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2024. The presentation will showcase data from their two-part, open-label, multicenter study (NCT05027139) evaluating evorpacept, a CD47 blocker, combined with zanidatamab, a dual HER2-targeted bispecific antibody. Dr. Alberto J. Montero from University Hospitals Seidman Cancer Center will present the findings on December 12, 2024.
ALX Oncology (Nasdaq: ALXO) ha annunciato che i risultati del loro studio di fase 1b/2 che combina evorpacept con zanidatamab nel cancro al seno metastatico HER2-positivo e HER2-low saranno presentati al San Antonio Breast Cancer Symposium (SABCS) a dicembre 2024. La presentazione metterà in evidenza i dati del loro studio multicentrico, a etichetta aperta e in due parti (NCT05027139) che valuta evorpacept, un bloccante CD47, in combinazione con zanidatamab, un anticorpo bispecifico mirato a duale HER2. Il Dr. Alberto J. Montero del Seidman Cancer Center delle University Hospitals presenterà i risultati il 12 dicembre 2024.
ALX Oncology (Nasdaq: ALXO) anunció que los resultados de su ensayo de fase 1b/2 que combina evorpacept con zanidatamab en cáncer de mama metastásico HER2-positivo y HER2-bajo se presentarán en el Simposio de Cáncer de Mama de San Antonio (SABCS) en diciembre de 2024. La presentación mostrará datos de su estudio multicéntrico, abierto y en dos partes (NCT05027139) que evalúa evorpacept, un bloqueador de CD47, combinado con zanidatamab, un anticuerpo bispecífico dirigido a HER2. El Dr. Alberto J. Montero del Seidman Cancer Center de University Hospitals presentará los hallazgos el 12 de diciembre de 2024.
ALX Oncology (Nasdaq: ALXO)는 evorpacept와 zanidatamab을 HER2-양성 및 HER2-저 메타스타틱 유방암의 1상 2상 시험에서 병용 요법한 결과를 2024년 12월 샌안토니오 유방암 심포지엄(SABCS)에서 발표할 것이라고 발표했습니다. 발표는 evorpacept(CD47 억제제)와 HER2를 이중적으로 겨냥한 bispecific 항체인 zanidatamab을 평가하는 두 부분으로 된 다기관 연구(NCT05027139)의 데이터를 보여줄 것입니다. University Hospitals Seidman Cancer Center의 Alberto J. Montero 박사가 2024년 12월 12일에 결과를 발표할 예정입니다.
ALX Oncology (Nasdaq: ALXO) a annoncé que les résultats de leur essai de phase 1b/2 combinant evorpacept avec zanidatamab dans le cancer du sein métastatique HER2-positif et HER2-faible seront présentés lors du San Antonio Breast Cancer Symposium (SABCS) en décembre 2024. La présentation mettra en avant les données de leur étude multicentrique, à ouvert et en deux parties (NCT05027139) évaluant evorpacept, un bloqueur de CD47, en combinaison avec zanidatamab, un anticorps bispécifique ciblant HER2. Le Dr Alberto J. Montero du Seidman Cancer Center des University Hospitals présentera les résultats le 12 décembre 2024.
ALX Oncology (Nasdaq: ALXO) gab bekannt, dass die Ergebnisse ihrer Phase 1b/2-Studie, die evorpacept mit zanidatamab bei HER2-positivem und HER2-niedrigem metastasiertem Brustkrebs kombiniert, auf dem San Antonio Breast Cancer Symposium (SABCS) im Dezember 2024 präsentiert werden. Die Präsentation wird Daten aus ihrer zweigeteilten, offenen, multizentrischen Studie (NCT05027139) zeigen, die evorpacept, einen CD47-Blocker, in Kombination mit zanidatamab, einem dual HER2-gerichteten bispezifischen Antikörper, bewertet. Dr. Alberto J. Montero vom Seidman Cancer Center der University Hospitals wird die Ergebnisse am 12. Dezember 2024 präsentieren.
- Clinical trial results deemed significant enough for presentation at major cancer symposium
- Strategic collaboration with Jazz Pharmaceuticals for combination therapy development
- None.
Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, today announced that results from a Phase 1b/2 combination trial evaluating ALX Oncology’s evorpacept in combination with Jazz Pharmaceuticals’ zanidatamab in HER2-positive and HER2-low metastatic breast cancer have been accepted for a poster spotlight presentation at the San Antonio Breast Cancer Symposium (SABCS), which will be held in San Antonio, Texas, from December 10-13, 2024.
The Phase 1b/2 clinical trial is a two-part, open-label, multicenter study (NCT05027139) that evaluated the potential of evorpacept in combination with zanidatamab as a novel treatment for patients with HER2-expressing breast cancer and other cancers. Data from this study will be summarized in the following poster spotlight presentation:
Title: Zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer: Results from a phase 1b/2 study
Abstract Number: SESS-2007
Presenter: Alberto J. Montero, M.D., MBA, Clinical Director, Breast Cancer Medical Oncology Program, Diana Hyland Endowed Chair for Breast Cancer, and Professor of Medicine at University Hospitals Seidman Cancer Center, Case Western Reserve University
Presentation Date and Time: Thursday, Dec. 12, 7:00 a.m. – 8:30 a.m. CST
Presentation ID: PS8-09
Location: Henry B. Gonzalez Convention Center, San Antonio, Texas
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
FAQ
What is the purpose of ALX Oncology's Phase 1b/2 trial for evorpacept (ALXO)?
When will ALX Oncology (ALXO) present their evorpacept trial results?
What type of cancer is ALX Oncology's evorpacept trial targeting (ALXO)?
